TREATMENT OF AGE-RELATED ANDROGEN DEFICIENCY IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

This paper reports the results of a comparative study evaluating the safety and efficacy of testosterone therapy in 44 patients with BPH and age-related androgen deficiency. All patients received a-blockers. The findings of the study showed a substantial improvement in the quality of life of patients in the study group that received testosterone therapy, compared with the control group treated with only a-blockers.

Texto integral

Acesso é fechado

Sobre autores

A. Kaprin

FSBIH «FMRC n.a. P.A. Herzen»

A. Kostin

FSBIH «FMRC n.a. P.A. Herzen»; FSAIE «People's Friendship University of Russia»

Department of Urology, Oncology and Radiology

I. Vinogradov

FSBIH «FMRC n.a. P.A. Herzen»; Medical Institute FGAIE of HE «People's Friendship University of Russia»

Email: iwinogradov@mail.ru
Department of Clinical Andrology

E. Magamadov

FSAIE «People's Friendship University of Russia»

Department of Urology, Oncology and Radiology

Bibliografia

  1. Нишлаг Э. Андрология. Мужское здоровье и дисфункция репродуктивной системы: пер. с англ. Под ред. Э. Нишлага, Г.М. Бере. М.: Мед. информ. агентство, 2005. 51 с.
  2. Nieschlag E., Swerdloff R., Behre H.M., Gooren L.J., Kaufman J.M., Legros J.J., Lunenfeld B., Morley J.E., Schulman C., Wang C., Weidner W, Wu F.C.; International Society of Andrology (ISA); International Society for the Study of the Aging Male (ISSAM); European Association of Urology (EAU). Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur. Urol. 2005;48(1):1-4.
  3. Nieschlag E., Behre H.M., Wieacker P, et al. Disorders at the testicular level. In: Nieschlag E., Behre H.M., Nieschlag S., eds. Andrology - male reproductive health and dysfunction. Berlin: Springer, 2010. P. 193-238.
  4. Глазнева С.Ю. Возрастной дефицит андрогенов у мужчин с расстройствами мочеиспускания. Дисс. канд. мед. наук. СПб., 2011.
  5. Калинченко С.Ю., Тюзиков И.А., Ворслов О.Л., Тишова Ю.А. Бессимптомная доброкачественная гиперплазия предстательной железы: лечить или не лечить? Эффективная фармакотерапия. Урология. 2012;4:20-22.
  6. Bhasin S., Cunningham G.R., Hayes F.J., Matsumoto A.M., Snyder P.J., Swerdloff R.S., Montori V.M. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2010;95(6):2536-2559.
  7. Caminiti G., Volterrani M., Iellano F., Marazzi G., Massaro R., Miceli M., Mammi C., Piepoli M., Fini M., Rosano G.M. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance and baroflex sensitivity in elderly patients with chronic heart failure: a doubleblind, placebo-controlled, randomized study. J. Am. Coll. Cardiol. 2009;54(10):919-927.
  8. Fernandez-Balsells M.M., Murad M.H., Lane M., Lampropulos J.F., Albuquerque F., Mullan R.J., Agrwal N., Elamin M.B., Gallegos-Orozco J.F., Wang A.T., Erwin P.J., Bhasin S., Montori V.M. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2010;95(6):2560-2575.
  9. Zitzmann M. Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men. Nat. Clin. Pract. Urol. 2007;4(3):161-166.
  10. Rosner W., Vesper H. Toward excellence in testosterone testing: a consensus statement. J. Clin. Endocrinol. Metab. 2010;95(10): 4542-4548.
  11. Seftel A. Testosterone replacement therapy for male hypogonadism: Pt 3. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Intern. J. of Impotence Research. 2007;19(1):2-24.
  12. Wang C., Harnett M., Dobs A., Swerdloff R.S. Pharmacokinetics and safety of long acting testosterone undecanoate injections in hypogonadal men: An 84-week phase III clinical trial. J. Androl. 2010;31(5):457-465.
  13. Калинченко С.Ю., Тюзиков И.А. Заболевания предстательной железы и метаболический синдром: новая патогенетическая концепция (литературный обзор). Медицинский алфавит. Больница. 2011;4:38-43.
  14. Kim S.J., Lee J., Nam C.M., Lee S.Y. Impact of obesity on metabolic syndrome among adolescents as compared with adults in Korea. Yonsei Med. J. 2011;52:746-752.
  15. Moon du G., Park M.G., Lee S.W., Park K., Park J.K., Kim S.W., Park N.C., Ahn T.Y., Paick J.S., Seo J.T., Yang D.Y., Lee J.Y., Kim J.J. The efficacy and safety of testosterone undecanoate (Nebido®) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J. Sex. Med. 2010;7(6):2253-2260.
  16. Nickel J.C., Me ndez-Probst C.E., Whelan T.F., Paterson R.F., Razvi H. Update: guidelines for the management of benign prostatic hyperplasia. Can. Urol. Assoc. J. 2010;4(5):310-316.
  17. Raynaud J.P. Testosterone deficiency syndrome: Treatment and cancer risk. J. Steroid Biochem. Mol. Biol. 2009;114(1-2):96-105.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2015

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies